Eventide Asset Management’s Blueprint Medicines BPMC Stock Holding History

Eventide Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-728,821	Closed	-$93.4M	–	245
2025 Q2	$93.4M	Sell	728,821 -133,728	-16%	-$13.9M	1.64%	15
2025 Q1	$76.3M	Buy	862,549 +264	+0%	+$25.8K	1.52%	15
2024 Q4	$75.2M	Buy	862,285 +513,581	+147%	+$47M	1.37%	20
2024 Q3	$32.3M	Buy	348,704 +117,019	+51%	+$11.6M	0.56%	62
2024 Q2	$25M	Hold	231,685	–	–	0.43%	77
2024 Q1	$22M	Sell	231,685 -80,689	-26%	-$6.92M	0.34%	85
2023 Q4	$28.8M	Sell	312,374 -126,126	-29%	-$8.17M	0.47%	64
2023 Q3	$22M	Hold	438,500	–	–	0.4%	75
2023 Q2	$27.7M	Hold	438,500	–	–	0.47%	67
2023 Q1	$19.7M	Hold	438,500	–	–	0.36%	85
2022 Q4	$19.2M	Hold	438,500	–	–	0.38%	78
2022 Q3	$28.9M	Hold	438,500	–	–	0.57%	55
2022 Q2	$22.1M	Sell	438,500 -154,000	-26%	-$9.02M	0.47%	66
2022 Q1	$37.8M	Buy	592,500 +196,700	+50%	+$14.1M	0.59%	55
2021 Q4	$42.4M	Buy	395,800 +39,800	+11%	+$4.16M	0.54%	64
2021 Q3	$36.6M	Sell	356,000 -105,712	-23%	-$9.84M	0.48%	67
2021 Q2	$40.6M	Sell	461,712 -288	-0.1%	-$26.4K	0.55%	57
2021 Q1	$44.9M	Hold	462,000	–	–	0.67%	57
2020 Q4	$51.8M	Hold	462,000	–	–	0.79%	41
2020 Q3	$42.8M	Hold	462,000	–	–	0.84%	43
2020 Q2	$36M	Hold	462,000	–	–	0.78%	47
2020 Q1	$27M	Hold	462,000	–	–	0.87%	45
2019 Q4	$37M	Hold	462,000	–	–	1.04%	39
2019 Q3	$33.9M	Hold	462,000	–	–	1.12%	30
2019 Q2	$43.6M	Hold	462,000	–	–	1.32%	21
2019 Q1	$37M	Buy	462,000 +50,000	+12%	+$3.69M	1.27%	23
2018 Q4	$22.2M	Buy	412,000 +130,000	+46%	+$7.9M	0.98%	36
2018 Q3	$22M	Buy	282,000 +132,000	+88%	+$9.17M	0.81%	43
2018 Q2	$9.52M	Hold	150,000	–	–	0.4%	71
2018 Q1	$13.8M	Hold	150,000	–	–	0.64%	57
2017 Q4	$11.3M	Sell	150,000 -86,000	-36%	-$6.05M	0.59%	60
2017 Q3	$16.4M	Sell	236,000 -29,000	-11%	-$1.55M	0.93%	43
2017 Q2	$13.4M	Hold	265,000	–	–	0.84%	48
2017 Q1	$10.6M	Hold	265,000	–	–	0.7%	49
2016 Q4	$7.43M	Hold	265,000	–	–	0.48%	60
2016 Q3	$7.87M	Hold	265,000	–	–	0.48%	58
2016 Q2	$5.37M	Buy	265,000 +18,500	+8%	+$336K	0.33%	71
2016 Q1	$4.45M	Hold	246,500	–	–	0.25%	80
2015 Q4	$6.49M	Buy	246,500 +139,500	+130%	+$3.14M	0.32%	75
2015 Q3	$2.28M	Buy	+107,000	New	+$2.96M	0.13%	96

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Eventide Asset Management's BPMC Position: Q3 2025 in Review

Eventide Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 728,821 shares — an estimated $93.4M sold.

Eventide Asset Management first reported a position in BPMC in Q3 2015 and held it in 40 quarters. The position peaked at $93.4M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Eventide Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Eventide Asset Management sold 728,821 Blueprint Medicines shares in Q3 2025, an estimated $93.4M.
Eventide Asset Management first reported a position in Blueprint Medicines in Q3 2015 and held it in 40 quarters.
Eventide Asset Management's Blueprint Medicines position peaked at $93.4M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Eventide Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.